Capital International Investors
QNCX icon

Capital International Investors’s Quince Therapeutics QNCX Stock Holding History

Capital International Investors’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,309
Closed -$18.4M – 479
2021
Q4 		$18.4M Sell
7,309
-7,570
-51% -$46.2M ﹤0.01% 409
2021
Q3 		$273M Buy
14,879
+1,196
+9% +$19M 0.06% 232
2021
Q2 		$145M Buy
13,683
+1,375
+11% +$11.5M 0.03% 271
2021
Q1 		$88.7M Sell
12,308
-594
-5% -$4.27M 0.02% 302
2020
Q4 		$71.7M Buy
12,902
+107
+0.8% +$948K 0.02% 308
2020
Q3 		$128M Buy
12,795
+3,882
+44% +$35.3M 0.04% 252
2020
Q2 		$82.5M Buy
8,913
+3,979
+81% +$36.5M 0.03% 270
2020
Q1 		$45M Buy
4,934
+144
+3% +$1.42M 0.02% 269
2019
Q4 		$53.8M Buy
4,790
+378
+9% +$2.28M 0.02% 261
2019
Q3 		$22M Buy
+4,412
New +$27.1M 0.01% 318

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors's QNCX Position: Q1 2022 in Review

Capital International Investors sold out of Quince Therapeutics (QNCX) in Q1 2022, closing a stake of 7,309 shares — an estimated $18.4M sold.

Capital International Investors first reported a position in QNCX in Q3 2019 and held it in 10 quarters. The position peaked at $273M in Q3 2021. 85 funds tracked by Wall St. Rank hold QNCX as of Q1 2022.

  • Capital International Investors reported no remaining Quince Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Capital International Investors sold 7,309 Quince Therapeutics shares in Q1 2022, an estimated $18.4M.
  • Capital International Investors first reported a position in Quince Therapeutics in Q3 2019 and held it in 10 quarters.
  • Capital International Investors's Quince Therapeutics position peaked at $273M in Q3 2021.
  • 85 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2022.

Based on Capital International Investors's 13F filing for Q1 2022, filed 16 May 2022.